H.C. Wainwright initiated coverage of Innoviva (INVA) with a Buy rating and $40 price target The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from “durable” royalty streams on mass market respiratory disease franchises.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva initiated with an Overweight at Cantor Fitzgerald
- Innoviva announces zoliflodacin NDA granted Priority Review by FDA
- Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin
- Innoviva Elects Board Members and Approves Compensation
- Innoviva subsidiary announces U.S. commercial availability of ZEVTERA